Previous 10 | Next 10 |
Emphasizes the Board’s Failure to Adequately Consider the Superior Acquisition Proposal Presented by Anson Funds and Cable Car Capital Believes the Misguided Transaction with Infinity Pharmaceuticals Will Continue to Destroy Stockholder Value Have Voted Against the Propos...
Event Available at 8:00 a.m. Eastern Time on June 19, 2023 MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinic...
2023-06-13 08:31:14 ET MEI Pharma ( NASDAQ: MEIP ) said on Tuesday that Brian Drazba is set to leave the post of CFO no later than Sep. 1, and the pharmaceutical company has hired Justin File as a successor. File joined the company on June 12 as executive vice president o...
MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, consistent with the Company’s succession planning, Brian Drazba’s tenure as Chief Financial Officer of the Comp...
2023-06-02 08:16:23 ET MEI Pharma ( NASDAQ: MEIP ) has announced that Daniel P. Gold, Ph.D’s tenure as the President and CEO of MEI will end on June 2, 2023 and the Co.’s board of directors has appointed David M. Urso as his successor. Mr. Urso, who join...
2023-06-01 16:50:12 ET Two private equity firms whose unsolicited bid for MEI Pharma ( NASDAQ: MEIP ) was rejected by the company's board called the rejection a "complete derogation of its fiduciary duties." Anson Funds and Cable Car Capital said that the board made its decision...
TORONTO and SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) -- Anson Funds (“Anson”) and Cable Car Capital LLC (“Cable Car” and, together with Anson, “we” or “us”), which collectively beneficially own approximately 14.8% of the outstanding com...
2023-06-01 08:47:48 ET MEI Pharma's ( NASDAQ: MEIP ) board has rejected an unsolicited offer from a group wanting to take the company private. The board said that the bid "significantly undervalues the Company, is not superior to the proposed transaction with Infinity Phar...
MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that its Board of Directors (the “Board”) reviewed and rejected the unsolicited and non-binding proposal received on May 23, 2023 from a group represented by Anson Advisors Inc. and Cable Car Capital LLC t...
2023-05-30 18:06:33 ET MEI Pharma ( NASDAQ: MEIP ) has received an unsolicited offer from a group wanting to take the company private. Shares are up ~10% in after-hours trading. The pharma said it received a non-binding proposal Tuesday from a group represented by Anso...
News, Short Squeeze, Breakout and More Instantly...
-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritizatio...
– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured Investment, Extending Operational Runway – MEI Pharma, Inc. ...